Journal
ANTIOXIDANTS & REDOX SIGNALING
Volume 27, Issue 12, Pages 874-911Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2017.7140
Keywords
thrombospondin-1; CD47; matricellular proteins; nitric oxide; reactive oxygen species; hydrogen sulfide
Funding
- Intramural Research Program of the NIH/NCI
- Institute for Transfusion Medicine
- Hemophilia Center of Western Pennsylvania
- Heart, Lung, Blood, and Vascular Medicine Institute of the University of Pittsburgh School of Medicine
- [2P01HL103455]
- [R01 HL-108954]
- [1R01HL112914]
Ask authors/readers for more resources
Significance: In contrast to structural elements of the extracellular matrix, matricellular proteins appear transiently during development and injury responses, but their sustained expression can contribute to chronic disease. Through interactions with other matrix components and specific cell surface receptors, matricellular proteins regulate multiple signaling pathways, including those mediated by reactive oxygen and nitrogen species and H2S. Dysregulation of matricellular proteins contributes to the pathogenesis of vascular diseases and cancer. Defining the molecular mechanisms and receptors involved is revealing new therapeutic opportunities. Recent Advances: Thrombospondin-1 (TSP1) regulates NO, H2S, and superoxide production and signaling in several cell types. The TSP1 receptor CD47 plays a central role in inhibition of NO signaling, but other TSP1 receptors also modulate redox signaling. The matricellular protein CCN1 engages some of the same receptors to regulate redox signaling, and ADAMTS1 regulates NO signaling in Marfan syndrome. In addition to mediating matricellular protein signaling, redox signaling is emerging as an important pathway that controls the expression of several matricellular proteins. Critical Issues: Redox signaling remains unexplored for many matricellular proteins. Their interactions with multiple cellular receptors remains an obstacle to defining signaling mechanisms, but improved transgenic models could overcome this barrier. Future Directions: Therapeutics targeting the TSP1 receptor CD47 may have beneficial effects for treating cardiovascular disease and cancer and have recently entered clinical trials. Biomarkers are needed to assess their effects on redox signaling in patients and to evaluate how these contribute to their therapeutic efficacy and potential side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available